Proton pump inhibitors (PPI) are acid-suppressive agents widely prescribed to patients with common gastrointestinal symptoms. The common belief that PPI have a safe profile and high efficacy level leads to PPI over-prescription. However, the physicians' knowledge about PPI could also contribute in this over-prescription. Thus, this study aimed to evaluate physicians' practice towards and knowledge about PPI prescription in Jeddah, Saudi Arabia. A crosssectional, questionnaire-based survey was conducted. The participants were randomly recruited from our hospital, Jeddah, Saudi Arabia between August and December 2013. The questionnaire comprised 15 items in three sections: questions regarding general background, practice of PPI prescription, and knowledge on PPI safety. The data were coded, entered, and analyzed using the Statistical Package for the Social Sciences software (SPSS), version 23.0.0. The results were presented as frequencies and percentages. In total, 112 physicians responded, and 58% reported prescribing PPIs to patients. Omeprazole was the preferred PPI prescribed. Only 20% of physicians consistently warned patients about the possible adverse effects. One-third reported that they discontinued PPIs after reassessment. Gastroesophageal reflux disease and peptic ulcer disease were the most common indications for PPI use. Approximately 60% of physicians prescribed PPIs for <6 months. Physician's knowledge about PPI adverse effects and drug-drug interactions were low. As a conclusion, physicians in our hospital showed low knowledge and poor adherence to guidelines regarding PPI prescription. Therefore, staff awareness programs and prescribing guidelines are required to ensure good clinical practice.
INTRODUCTION
Proton pump inhibitors (PPIs) are acid-suppressive agents widely prescribed to patients with common gastrointestinal symptoms. PPIs irreversibly inhibit H+/K+-ATPase, the final step of gastric acid production [1] . Thus, they are the most potent anti-secretory agents available for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), dyspepsia and the eradication of Helicobacter pylori. Moreover, PPIs are the most effective prophylaxis against stress-and nonsteroidal anti-inflammatory (NSAID)-induced PUD [2, 3] . Short-term PPI administration is generally safe and has infrequent minor side effects. However, serious side effects associated with the continuous use of PPIs have been reported in the literature [4] . A growing body of evidence shows that these side effects include metabolic effects on bone density, alterations in the absorption of vitamins and minerals and in pharmacokinetics/pharmacodynamics and related drug interactions, and Clostridium difficile infection risk [4] . The risk of developing PPI side effects has been shown to correlate with the duration of PPI use [4, 5] . The common belief that PPIs have a safe profile and high level of efficacy enhances PPI over-prescription by physicians worldwide [6, 7] . In 2013, it had been estimated that more than 15 million prescriptions are written for patients in the United States [8] . Furthermore, previous reports have shown that more than half of the inpatients receiving PPIs have no risk factors for nosocomial upper gastrointestinal tract bleeding, and PPIs may be continued unnecessarily after hospital discharge [9] . A lack of guidance for PPI prescription upon discharge leads to the unnecessary continuation of the medication [10] . Moreover, PPIs are commonly prescribed for treating uninvestigated upper GI symptoms and continuing unnecessarily for years. To reduce the risk of PPI over-prescription, physicians should tailor the use of these drugs according to the risks and benefits for each patient. However, although many previous studies have reported PPI overprescription, [7, 10, 11] physician knowledge and attitudes regarding PPI prescription have only rarely been assessed [12, 13, 14] . Thus, this study evaluated physicians' practice and knowledge about PPIs prescription at our hospital in Jeddah, Saudi Arabia.
METHODS

Participants
This quantitative, descriptive, cross-sectional study was conducted to assess the practice and knowledge of health care providers at our hospital. The physicians included house officers (interns), resident doctors, registrars, and consultants from the departments of emergency, obstetrics and gynecology, medicine, and surgery were invited to participate in the study. The study was explained to the participants before they responded to the questionnaire. Participants were free to skip any questions and were not paid for participating.
Sample size calculation
The estimated sample size for the study was 142. The sample size was calculated using an error margin of 10%, a confidence interval of 99%, and population size of 983 that equal to the number of the medical staff (including medical trainees).
Study design
The study was carried out between August and December 2013 with a self-administrated questionnaire adapted from similar studies [13, 15] . It was written in English, reviewed by an internal medicine consultant, and comprised 15 items in three sections. The first section contained general questions about qualifying medical degree and specialty. The second section consisted of 10 questions regarding the practice of PPI prescription, including whether respondents had ever prescribed PPIs for their patients, and if so, the preferred PPI prescribed, the most common indications for prescribing PPIs, the length of PPI prescription, whether the need for chronic PPI therapy in patients was assessed, whether PPI administration was stopped after reassessment, whether patients were habitually instructed about when to use PPIs in relation to meals, whether possible side effects were usually explained to patients, and whether patients were educated about lifestyle modification as an adjuvant management for their conditions. The last section included three questions regarding knowledge about PPI safety, adverse effects, and potential drug-drug interactions. The study protocol and questionnaire were approved by the KAUH ethics committee.
Statistical analysis
The data were coded, entered, and analyzed using the Statistical Package for the Social Sciences software (SPSS), version 23.0.0. The results were presented as frequencies and percentages.
RESULTS
General characteristics of the respondents
A total of 112 physicians completed the questionnaire. The response rate was 79%; the low response rate was mainly due to unavailability of physicians' time. The majority of these physicians were house officers (41.2%) and residents (32.1%) but a smaller percentage of consultants, specialists, and general practitioners were also included (Table 1) . Thirty-four percent of the physicians were from the medicine department, 26% from surgery, 20.5% from obstetrics and gynecology, and 19.6% from the emergency department. 
PPI prescription practices
As shown in Table 2 , more than half of the respondents had prescribed PPIs to their patients. The most frequently prescribed PPI was omeprazole (47.3%), followed closely by pantoprazole (30.4%) and esomeprazole (22.3%). However, lansoprazole, dexlansoprazole, or rabeprazole were not routinely prescribed by the physicians. One-third of the physicians had advised patients to use PPIs until their symptoms disappeared, and the rest advised patients to use them less than 6 months. Half of the physicians habitually reassessed the use of PPI therapy in their patients in each clinic visit: 36.6% reported that they discontinued PPI therapy when they considered it no longer necessary. Two-thirds of the physicians correctly instructed patients to use PPIs before a meal, whereas 21.4% responded that they had no knowledge about the optimal time for administration. Moreover, 20% of physicians always warned patients about possible side effects, whereas 64% of the physicians educated their patients about lifestyle modification as a means of managing their conditions. The most common conditions for which physicians prescribed PPIs were GERD (68.8%) and PUD (66.1%), as shown in Table 3 . 
Knowledge of PPI actions and possible side effects
The respondents' general knowledge about PPI therapy was measured along with their knowledge of possible side effects. Table 4 shows a summary of the responses related to PPI possible side effects. The majority of the physicians were unable to identify some of the possible side effects of PPI therapy. Only 15.2% were aware of the increased risk for microscopic colitis; 18.8% of the increased risk for pneumonia, 25% of the increased risk for C. difficile infection, and 24% of the increased risk for osteoporosis. Next, physician knowledge about PPI drug interactions was evaluated. Approximately half of the participants correctly identified the possible PPI drug interactions with ketoconazole, digoxin, clopidogrel, and drugs metabolized by liver enzymes (Table 5) . 
DISCUSSION
Although the safety profile of PPIs and their high efficacy level explains the over-prescription of PPI, [6, 7, 11] low physician knowledge regarding the PPI prescribing guidelines could also excessively contribute on their over-prescription. Therefore, this study aimed to evaluate physicians' practice towards and knowledge about PPI prescription at our hospital in Jeddah, Saudi Arabia. To the best of our knowledge, this study is the first to survey PPI prescription practices in an Arab country. A better understanding of physician prescribing practices and knowledge about PPIs may play a key role in the implementation of institutional guidelines to ensure good clinical practice. As a consequence, this could leads to the development of better guidelines. The results of our survey revealed that more than half of the physicians prescribed PPIs to their patients. This is consistent with results from surveys of emergency physicians in India [13] . Physicians participating in both these studies reported that GERD is the most common indication for prescribing PPI therapy. However, unlike the physicians in this study who routinely prescribed PPI for longer than 2 weeks, emergency physicians in India preferred to prescribe PPIs for <1 week [13] . Similar to other studies conducted to evaluate the use of PPIs, the present study found that physicians preferred omeprazole to other PPIs [6] . This finding is alarming because omeprazole is the most costly PPI, [16] and it has a comparatively greater potential for drug-drug interactions [17] . Although most of the physicians in our study habitually reassessed the need for PPI therapy in their patients, only one-third discontinued PPIs after reassessment. This practice may be due to a lack of knowledge about step-down guidelines that recommend using "on-demand" dosing or reducing PPI dose for patients with heartburn, GERD, or esophagitis after complete 4 weeks of PPI treatment [18] . Failure to adhere to reassessment and step-down guidelines may contribute to the over-prescription of PPIs. Moreover, many studies have shown that prophylaxis PPIs are prescribed inappropriately to hospitalized patients at low risk for stress ulcers [7, 11, 15] and then continued after discharge [10] . In all cases, the need for PPIs must be reassessed, and a step-down strategy must be adopted [18] . Current evidence supports the superiority of PPIs for the treatment of GERD, PU, and H. pylori infection, but the recommendation is to use PPIs for no longer than 12 weeks. The only evidence-based indications for long-term PPI use are the prophylaxis of NSAIDinduced gastropathy [2] and the treatment for Barrett's esophagus and Zollinger-Ellison syndrome [19] . Physician practices reflect the level of knowledge, and therefore, physician knowledge of PPI use and safety were evaluated in this study. The results showed that the majority of physicians considered PPIs to have low toxicity, which is a common belief among physicians worldwide [8] . However, a study of physicians at Baystate Medical Center (Springfield, MA, USA) showed that more than half were unable to identify the potential side effects of PPIs [15] . Similarly, a study conducted in India showed that emergency physicians had low knowledge about PPI side effects [13] . One of the alarming findings of the present study is that physicians do not habitually warn their patients about the side effects of PPI therapy. The strong physician belief that PPIs have high efficacy and safety profiles may be the most important contribution to PPI overprescription. On the contrary, physicians showed better knowledge of PPI drug-drug interactions. This finding is clinically important because there is a risk of polypharmacy with PPIs, particularly in hospitalized elderly patients taking prophylaxis PPIs [17] . PPIs interact with concomitantly administered medications, primarily via one of the following three mechanisms [20] . PPIs can interfere with the absorption of weakly acidic or basic drugs such as ketoconazole and digoxin as a result of increased gastric pH [4] . Additionally, PPIs are metabolized by hepatic cytochrome P450 while simultaneously inhibiting this enzyme. Therefore, when co-administered with medications such as phenytoin and warfarin, PPIs increase the potential for their toxicity. Finally, PPIs may delay the renal elimination of drugs such as methotrexate, [4, 17] and although the exact mechanism is unknown, PPIs can decrease the efficacy of clopidogrel [4, 17] .
CONCLUSION
Our study sheds some light on the physician-related factors in PPI over-prescription. Low physician knowledge about the use and effects of PPIs, particularly adverse effects, could be the main factor contributing to PPI over-prescription in our hospital. In addition to the safety concerns related to PPI overprescription, cost is a concern because PPIs are relatively expensive. In 2007, PPIs were among the top ten leading prescription drugs in the United States.21 Therefore, this study highlights the necessity for staff awareness about the clinical indications, duration, and safety of PPI therapy. Moreover, prescribing guidelines must be developed for PPI reassessment and step-down strategies to ensure good practice.
This study may contribute toward evidence-based practice with strict prescription protocols and, thus, avoid unnecessary side effects and costs.
Strengths and limitations of this study
• This study is the first to evaluate physicians' practice and knowledge of PPI prescription in an Arab country.
• The study highlighted the necessary of prescription guidelines to ensure good practice in PPI therapy.
• The results from this study may not be generalized because it was conducted at a single hospital with a relatively small sample size. Furthermore, our hospital is an academic hospital, which may have unintentionally biased the sample of respondents.
• The respondents included more number of junior physicians (interns) than consultants. Therefore, a wider national survey may be needed to confirm our findings.
